The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

TaiMed Biologics to present 24-week HIV data on eight-week regimen

Nov 5, 2026 00:00 (8h ago)

Verifying

TaiMed Biologics will present clinical data on its TMB-365/TMB-380 HIV maintenance regimen.
The Phase 2a study covers 24 weeks with dosing every eight weeks.
TaiMed will also present an encore poster from its Phase 1 TMB-365 study.